FDA Brief

Warning letters Drugs

FDA warning letter to

premiumlightsupplier.com

High riskIssued Mar 30, 2022Posted Apr 12, 2022Center for Drug Evaluation and Research | CDER

FDA and DEA warned premiumlightsupplier.com that it unlawfully sells Schedule II stimulants, including Adderall, online without prescriptions or DEA registration.

What happened

DEA reviewed the website and found it offered to distribute or dispense Schedule II stimulants, including amphetamine products, and advertised their sale without a modified DEA registration. FDA reviewed the site and found it offered “Adderall 20mg | 30mg” for sale without requiring a prescription, making the drug misbranded. The letter cites risks of diversion, nonmedical use, and contaminated or counterfeit drugs from online sellers.

What FDA found

  1. The website offered to sell Schedule II stimulants, including amphetamine products, over the internet without the special DEA registration required for online controlled-substance sales.

    21 U.S.C. § 841(h)
  2. The website advertised controlled substances online even though it did not have the required modified DEA registration.

    21 U.S.C. § 843(c)
  3. The website offered Adderall, a prescription stimulant, for sale without requiring a prescription.

    21 U.S.C. § 353(b)(1); FD&C Act § 503(b)(1)
  4. Selling a prescription drug without a prescription makes the drug misbranded while held for sale.

    21 U.S.C. § 331(k); FD&C Act § 301(k)
  5. Offering the misbranded Adderall to U.S. consumers caused it to be introduced into interstate commerce.

    21 U.S.C. § 331(a); FD&C Act § 301(a)

What FDA wants

FDA and DEA ask the company to notify both agencies in writing within 15 working days of the steps it has taken or will take to correct the violations and prevent recurrence. If the company believes it is compliant, it must send its reasoning and supporting information within the same period.

Who should pay attention

  • online pharmacies and telehealth sites selling controlled substances
  • domain registrars and hosting providers for drug-selling websites
  • brand owners of prescription stimulants

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. onlineotcmeds.com

    FDA warned onlineotcmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and Schedule II stimulants to U.S. consumers online.

    High risk
  2. www.usmedschoice.com

    FDA warned www.usmedschoice.com for selling unapproved and misbranded opioids, benzodiazepines, and stimulants online without prescriptions.

    High risk
  3. Aytu Biopharma

    FDA says Aytu Biopharma’s sponsored links for ADHD drug Cotempla XR-ODT are false or misleading and misbrand it.

    High risk
  4. Aytu Biopharma

    FDA warned Aytu Biopharma that sponsored links for ADHD drug Adzenys XR-ODT are false or misleading because they omit risk information.

    High risk